TIDMNSCI
RNS Number : 4509V
NetScientific PLC
18 April 2016
NetScientific
("NetScientific" or the "Company" or the "Group")
NetScientific portfolio company Vortex Biosciences introduces
novel fully automated circulating tumour cell enrichment instrument
VTX-1 at AACR
London, UK - 18 April 2016 - NetScientific plc (AIM:NSCI), the
transatlantic healthcare technology group, notes that its portfolio
company, Vortex Biosciences, will preview VTX-1, a fully automated
system for the efficient enrichment of intact circulating tumour
cells (CTCs) from whole blood, at the American Association for
Cancer Research (AACR) Annual Meeting held in New Orleans. Data
presented, see separate press release below, at AACR demonstrate
the ability of Vortex's technology to rapidly collect highly
enriched populations of CTCs, undamaged by labels or reagents, for
colorectal and prostate cancer research.
Commenting on the news, NetScientific's Chief Executive Officer,
Francois R. Martelet said: "We believe Vortex's technology, which
is targeting a commercial launch in early 2017, could be of great
benefit to the field of cancer research by providing a rapid,
reliable and convenient way to collect circulating tumour cells,
accelerating the development of innovative diagnostics and
therapeutics."
The full text of the announcement from Vortex Biosciences can be
found below.
- Ends -
For more information, please contact:
NetScientific Tel: +44 (0)20 3514 1800
François R. Martelet,
M.D., CEO
Mark Nanovich, Interim
CFO
Investec (NOMAD and Tel: +44 (0)20 7597 4000
broker)
Gary Clarence / Daniel
Adams
Consilium Strategic Tel: +44 (0)20 3709 5700
Communications netscientific@consilium-comms.com
Mary-Jane Elliott /
Chris Gardner / Jessica
Hodgson / Chris Welsh
/ Laura Thornton
About NetScientific Plc
NetScientific is a biomedical and healthcare technology group
that funds and develops technologies that offer transformative
benefits to people's lives and society through improved diagnosis,
prognosis and treatment. For more information, please visit the
website at www.netscientific.net.
Vortex Biosciences Previews Fully Automated System for
Label-Free, Intact CTC Enrichment
Studies Presented at AACR Support Application of Vortex's Liquid
Biopsy
Technology for Isolating Circulating Tumor Cells in Colorectal
and Prostate Cancer Research
MENLO PARK, CA, April 18, 2016 - Vortex Biosciences previewed
the VTX-1, a fully automated system for the efficient enrichment of
intact circulating tumor cells (CTCs) from whole blood, at the
American Association for Cancer Research (AACR) Annual Meeting 2016
(April 16-20, New Orleans). Data presented at AACR demonstrate the
ability of Vortex's technology to rapidly collect highly enriched
populations of CTCs, undamaged by labels or reagents, for
colorectal and prostate cancer research.
Representative of cancer status in the patient, CTCs, shed by
tumors, can potentially reveal disease recurrence or disease
progression earlier than imaging and more reliably compared with
standard biomarkers. Previous research demonstrated the performance
of Vortex's technology in isolating CTCs in breast and lung cancer
research.(1)
"As we move towards commercialization of the VTX-1 system, the
studies presented at AACR confirm the ability of Vortex's
technology to isolate viable CTCs for a broad range of downstream
assays," explained Vortex CEO Gene Walther. "Empowering cancer
researchers with a rapid, reliable and convenient solution to
collect CTCs could advance cancer research and accelerate the
development of innovative diagnostics and therapeutics."
CTC Isolation
CTCs are relatively scarce, with concentrations as low as 1-10
CTCs/mL of whole blood, against a background of millions of white
blood cells and billions of red blood cells. CTC enrichment
technologies have been limited by complex sample processing, poor
scalability, low sample purity, reliance on cell surface proteins
for isolation, and dilute output volumes that require additional
cell concentration steps.(1)
The Vortex VTX-1 system is a fully automated benchtop system for
collecting intact CTCs using microfluidic technology. Inside the
VTX-1 chip, unlabeled CTCs in whole blood are trapped in microscale
vortices while smaller red and white blood cells pass through.
After selective trapping into the microfluidic chambers, CTCs can
be flushed and collected into a variety of containers for
downstream analysis.
Studies at AACR
CTCs were isolated from colorectal cancer (CRC) patient blood
samples using Vortex's microfluidic technology in Enumeration and
mutational profiling of CTCs, and comparison to ctDNA and
colorectal cancer liver metastases(2) (poster #3149, to be
presented 8 a.m.-12 p.m., Tuesday, April 19). In this study, nearly
25-fold more CTCs were found in preoperatively collected CRC
patient samples than in age-matched healthy controls, and 80% of
all CRC samples were identified as positive for CTCs. The number of
CTCs for each patient showed a close correlation with clinical
parameters and circulating tumor DNA levels. Compared with
carcinoembryonic antigen value (the standard biomarker for CRC) or
imaging, CTCs and CTC mutational profiles provided earlier
indicators of minimal residual disease and anticipated tumor
recurrence.
Another study, Label free collection of prostate circulating
tumor cells using microfluidic Vortex technology(3) (poster #4967,
to be presented 8 a.m.-12 p.m., Wednesday, April 20), demonstrates
the ability of Vortex's technology to rapidly collect pure
populations of CTCs from blood samples in metastatic prostate
cancer.
In a third study, Vortex technology for label-free enrichment of
CTC from mouse xenograft models(4) (poster #1525, to be presented 8
a.m.-12 p.m., Monday, April 18) investigators used Vortex's
technology to isolate CTCs from mouse blood. The investigators
observed both high capture efficiency and high CTC purity,
suggesting that the technology can be applied in mouse studies to
facilitate discovery of new therapeutic targets and development of
personalized medicine.
"These studies illustrate the potential of Vortex's microfluidic
technology to help cancer researchers advance detection of cancer
disease recurrence and progression earlier and more reliably
compared with standard approaches," explained investigator Dr. Dino
Di Carlo, Professor in the Department of Bioengineering at UCLA,
where he directs the Microfluidic Biotechnology Laboratory.
About Vortex Biosciences
Vortex Biosciences is a cancer research and diagnostics company
that integrates cancer biology, microfluidic engineering and
informatics to develop tools for isolating and characterizing
circulating tumor cells. The Vortex VTX-1 instrument harvests
intact circulating tumor cells from whole blood samples for use in
downstream research and clinical applications such as patient
stratification in clinical trials, monitoring disease progression
and drug treatment effectiveness. With a mission to enable
noninvasive diagnosis of cancer and real-time monitoring throughout
a patient's treatment, Vortex is at the forefront of accelerating
cancer research and improving patient outcomes. Vortex is a core
subsidiary of NetScientific plc, a transatlantic healthcare
technology group with an investment strategy focused on sourcing,
funding and commercializing technologies that significantly improve
the health and well-being of people with chronic diseases. For more
information, visit www.vortexbiosciences.com.
# # #
References
1. Che J et al. Classification of large circulating tumor cells
isolated with ultrahigh throughput microfluidic Vortex technology.
Oncotarget, February 2016.
2. Kidess-Sigal E et al. Enumeration and mutational profiling of
CTCs, and comparison to ctDNA and colorectal cancer liver
metastases. Poster presentation 3149 at the American Association
for Cancer Research Annual Meeting, April 19, 2016.
3. Pao E et al. Label free collection of prostate circulating
tumor cells using microfluidic Vortex technology. Poster
presentation 4967 at the American Association for Cancer Research
Annual Meeting, April 20, 2016.
4. Heirich K et al. Vortex technology for label-free enrichment
of CTC from mouse xenograft models. Poster presentation 1525 at the
American Association for Cancer Research Annual Meeting, April 18,
2016.
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCUBRURNRASAUR
(END) Dow Jones Newswires
April 18, 2016 02:00 ET (06:00 GMT)
Netscientific (LSE:NSCI)
Gráfico Histórico do Ativo
De Jun 2024 até Jul 2024
Netscientific (LSE:NSCI)
Gráfico Histórico do Ativo
De Jul 2023 até Jul 2024